FDA-cleared profile

ANDI

Imeka Solutions, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: ANDI processes diffusion-weighted MRI with auxiliary T1 imaging to create 3D white-matter tract maps and microstructure reports for trained medical professionals as adjunctive measurement information, not diagnosis.

Clinical role
Diffusion MRI tractography, white-matter microstructure measurement, and adjunctive visualization support
Images and patients
MRI · Brain
Key limitation
Keep in mind: ANDI measures white-matter tracts only and does not predict, diagnose, or interpret brain health; it is adjunctive and not a diagnostic aid. A physician must review all clinical information. The exact packet distinguishes NIfTI/API input from DICOM-compliant report output, so local interface compatibility requires confirmation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: ANDI processes diffusion-weighted MRI with auxiliary T1 imaging to create 3D white-matter tract maps and microstructure reports for trained medical professionals as adjunctive measurement information, not diagnosis.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: Diffusion-weighted MRI with T1-weighted images as auxiliary input; the exact comparison describes NIfTI image input and an API-based interface, with reversed-phase-encoded B=0 as an optional input. The exact acquisition protocol was not established.
  • Who uses it?Intended users: Medical professionals, including neurologists and radiologists; trained professionals make the final decision.
  • What does the software produce?Output: 3D white-matter tract maps and a CSD-based microstructure report providing reference information for comparison with a control population and, optionally, longitudinal comparison; the subject device output is a DICOM encapsulated PDF report supported by RIS/PACS.
  • What is its most important limitation?Key limitation: ANDI measures white-matter tracts only and does not predict, diagnose, or interpret brain health; it is adjunctive and not a diagnostic aid. A physician must review all clinical information. The exact packet distinguishes NIfTI/API input from DICOM-compliant report output, so local interface compatibility requires confirmation.

Clinical takeaway. Clinical role: ANDI processes diffusion-weighted MRI with auxiliary T1 imaging to create 3D white-matter tract maps and microstructure reports for trained medical professionals as adjunctive measurement information, not diagnosis.

Evidence takeaway. Evidence from the reviewed source record: The FDA describes non-clinical performance testing of measured endpoints, AI brain extraction, processing-pipeline robustness, and report content/structure; it states that no clinical studies were considered necessary or performed.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
ANDI processes diffusion-weighted MRI with auxiliary T1 imaging to create 3D white-matter tract maps and microstructure reports for trained medical professionals as adjunctive measurement information, not diagnosis.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Diffusion MRI tractography, white-matter microstructure measurement, and adjunctive visualization support
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Diffusion-weighted MRI with T1-weighted images as auxiliary input; the exact comparison describes NIfTI image input and an API-based interface, with reversed-phase-encoded B=0 as an optional input. The exact acquisition protocol was not established.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
3D white-matter tract maps and a CSD-based microstructure report providing reference information for comparison with a control population and, optionally, longitudinal comparison; the subject device output is a DICOM encapsulated PDF report supported by RIS/PACS.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Clinical neuroimaging for trained medical professionals such as neurologists and radiologists; the output is adjunctive to standard-of-care evaluation.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Medical professionals, including neurologists and radiologists; trained professionals make the final decision.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
ANDI measures white-matter tracts only and does not predict, diagnose, or interpret brain health; it is adjunctive and not a diagnostic aid. A physician must review all clinical information. The exact packet distinguishes NIfTI/API input from DICOM-compliant report output, so local interface compatibility requires confirmation.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The FDA describes non-clinical performance testing of measured endpoints, AI brain extraction, processing-pipeline robustness, and report content/structure; it states that no clinical studies were considered necessary or performed.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA describes non-clinical performance testing of measured endpoints, AI brain extraction, processing-pipeline robustness, and report content/structure; it states that no clinical studies were considered necessary or performed.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

ANDI non-clinical performance and report validation

  • DesignNon-clinical software performance, robustness, and report-structure validation
  • PopulationPredefined software test protocols covering measured endpoints, AI brain extraction, processing-pipeline robustness, and a summative report evaluation; sample counts were not stated in the reviewed summary.
  • Scopeexact submission
  • Tested versionANDI submitted in K230913; build not stated
  • IndependenceIndependence not established

K230913

The FDA states that no clinical studies were considered necessary or performed. No independent investigators or sponsorship were established.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Diffusion-weighted MRI with T1-weighted images as auxiliary input; the exact comparison describes NIfTI image input and an API-based interface, with reversed-phase-encoded B=0 as an optional input. The exact acquisition protocol was not established.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K230913: ANDI

  2. Routing

    Source context, not route validation: The exact submission describes API-based image input and report output, NIfTI input, and DICOM encapsulated PDF output supported by RIS/PACS; this is not evidence that the subject device accepts DICOM images directly as input.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K230913: ANDI

  3. AI processing

    Source context, not route validation: Cloud-based image-processing software

    Scope: Exact FDA submission. The FDA comparison describes both subject and predicate as cloud-based; current hosting region, retention, and data-flow controls were not separately established.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K230913: ANDI

  4. Returned objects

    Source context, not route validation: 3D white-matter tract maps and a CSD-based microstructure report providing reference information for comparison with a control population and, optionally, longitudinal comparison; the subject device output is a DICOM encapsulated PDF report supported by RIS/PACS.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K230913: ANDI

  5. Viewer/worklist/report

    Unresolved route: 3D white-matter tract maps and a CSD-based microstructure report providing reference information for comparison with a control population and, optionally, longitudinal comparison; the subject device output is a DICOM encapsulated PDF report supported by RIS/PACS.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K230913: ANDI

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud-based image-processing software
  • Exact FDA submission
  • Checked 2026-09-07

The FDA comparison describes both subject and predicate as cloud-based; current hosting region, retention, and data-flow controls were not separately established.

Integration
The exact submission describes API-based image input and report output, NIfTI input, and DICOM encapsulated PDF output supported by RIS/PACS; this is not evidence that the subject device accepts DICOM images directly as input.
  • Exact FDA submission
  • Checked 2026-09-07

API-to-RIS/PACS report workflow

The exact submission describes an API for image input and report output, NIfTI input, and a DICOM encapsulated PDF report supported by RIS/PACS.

exact submission · checked 2026-09-07

Current ANDI quantitative DTI workflow

Imeka's official ANDI page describes a current family workflow from raw diffusion data to a quantitative report, including automated tract analysis, normative comparisons, longitudinal views, and a secure cloud environment; this current family description is not promoted to exact K230913 version performance or security evidence.

product family · checked 2026-09-07

Current family page context only; exact-version and local interface compatibility require confirmation.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K230913
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-07-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
10Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed, ClinicalTrials.gov, and exact-submission recall metadata candidates were screened by identifier and count. The records were not treated as a full paper, trial, or postmarket review. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public amount, range, currency, geography, or contract term was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Imeka ANDI reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Only trade press (BioWorld, 2023-08-24) mentions new CPT Category III codes for quantitative brain MRI; no vendor or payer page names a code for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    The reviewed sources do not establish a scoped security audit, certification, or control set.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Training, credentialing, and implementation support terms were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Current post-deployment monitoring and change-control practices were not established.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K230913: ANDI

    U.S. Food and Drug Administration - Published 2023-07-25 - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ANDI model card (K230913)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, output, limitations, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. ANDI quantitative diffusion MRI workflow

    Imeka Solutions Inc. - Accessed 2026-09-08

    Scope: productFamily, clinicalWorkflow, reports, implementationCapabilities

Research history

  1. K230913 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history